GlassScriptPhysician profile
Bogdan Nedelescu
NPI 1699732800
$49,417.99
in general payments reported to CMS, 2019-2025
73 companies · $10K in 2025
The $10K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,355 · 2020: $1,953 · 2021: $4,011 · 2022: $3,497 · 2023: $11K · 2024: $15K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $13K · Travel and Lodging: $4,238 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,150 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,917.43 |
| Consulting Fee | $13,050.00 |
| Travel and Lodging | $4,237.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,150.00 |
| Education | $247.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21,466.88 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $3,447.55 | 2019-2025 | Airsupra, Farxiga, Tezspire |
| Eli Lilly and Company | $1,950.00 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $1,552.35 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $1,387.45 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,381.66 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,241.59 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $1,126.70 | 2020-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $948.11 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $938.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $769.91 | 2019-2024 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Amgen INC. | $766.35 | 2019-2025 | Repatha, Otezla, Repatha |
| Nestle Healthcare Nutrition INC. | $658.23 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $633.51 | 2019-2025 | |
| Gilead Sciences, INC. | $631.05 | 2019-2025 |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $606.80 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $580.93 | 2022-2025 | |
| Pfizer INC. | $562.96 | 2019-2025 | |
| Astellas Pharma US INC | $492.00 | 2019-2024 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $467.36 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $452.97 | 2019-2024 | Ozempic, Rybelsus |
| Corcept Therapeutics | $439.84 | 2023-2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $395.91 | 2019-2023 | Xifaxan |
| Exact Sciences Corporation | $373.93 | 2023-2025 | Cologuard Collection Kit |
| Biogen, INC. | $372.07 | 2020-2025 | Leqembi |
| E.R. Squibb & Sons, L.L.C. | $352.14 | 2019-2024 | Eliquis |
| Lundbeck LLC | $339.10 | 2022-2025 | Rexulti |
| Allergan, INC. | $333.91 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $328.50 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $319.19 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Abiomed | $300.96 | 2024-2025 | Impella |
| Regeneron Healthcare Solutions, INC. | $299.74 | 2019-2025 | Dupixent |
| Avanir Pharmaceuticals, INC. | $266.37 | 2019-2022 | |
| Qiagen, LLC | $256.52 | 2019-2024 | |
| Daiichi Sankyo INC. | $252.87 | 2022-2024 | Injectafer |
| Nuvasive, INC. | $237.48 | 2019 | |
| Aimmune Therapeutics, INC. | $216.17 | 2024-2025 | Zenpep, Vowst |
| Endo Pharmaceuticals INC. | $212.19 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $168.12 | 2025 | Caplyta |
| Philips North America LLC | $166.88 | 2022-2024 | (Ak6) Vest Therapy |
| Acadia Pharmaceuticals INC | $151.40 | 2019-2025 | Nuplazid |
| Esperion Therapeutics, INC. | $141.01 | 2021-2024 | Nexletol |
| Neurelis, INC. | $137.91 | 2021-2025 | Valtoco |
| Ardelyx, INC. | $137.83 | 2024-2025 | Ibsrela |
| Edw Pharma, INC. | $114.28 | 2019 | |
| Verona Pharma, INC. | $107.18 | 2025 | Ohtuvayre |
| Scilex Pharmaceuticals INC. | $83.93 | 2019 | |
| Cmp Pharma, INC. | $72.26 | 2022-2023 | Carospir, Norliqva, Tadliq |
| Medtronic, INC. | $63.95 | 2023-2025 | Intellis Adaptivestim, Venaseal |
| Vifor Pharma, INC. | $62.61 | 2021 | |
| Eisai INC. | $56.76 | 2020-2023 | |
| Amarin Pharma, INC. | $52.74 | 2021 | |
| Melinta Therapeutics, LLC | $47.07 | 2019 | |
| Mylan Specialty L.P. | $42.17 | 2024 | Yupelri |
| Inspire Medical Systems, INC. | $39.41 | 2025 | Inspire |
| Collegium Pharmaceutical, INC. | $38.48 | 2020 | |
| Alnylam Pharmaceuticals INC. | $37.44 | 2025 | Amvuttra |
| Sanofi Pasteur INC. | $34.43 | 2019-2025 | |
| Quidel Corporation | $32.21 | 2022 | |
| Viiv Healthcare Company | $31.35 | 2023 | Apretude |
| Sun Pharmaceutical Industries INC. | $24.79 | 2021 | |
| Almatica Pharma LLC | $21.95 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.70 | 2023 | Quviviq |
| Redhill Biopharma INC. | $20.89 | 2020 | |
| Alexion Pharmaceuticals, INC. | $20.60 | 2020 | |
| Xeris Pharmaceuticals, INC. | $20.45 | 2021 | |
| Bardy Diagnostics, INC. | $20.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.19 | 2021 | |
| Inogen, INC. | $15.24 | 2024 | |
| Pulmonx Corporation | $15.20 | 2024 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Merck Sharp & Dohme LLC | $15.08 | 2021 | |
| Nabriva Therapeutics, Plc | $14.14 | 2020 | |
| Biodelivery Sciences International, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bogdan Nedelescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.